Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

@article{Jones2016DalbavancinAW,
  title={Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).},
  author={Ronald N. Jones and Jason E Schuchert and Rodrigo Elisandro Mendes},
  journal={Antimicrobial agents and chemotherapy},
  year={2016},
  volume={60 6},
  pages={
          3419-25
        }
}
Dalbavancin, a novel lipoglycopeptide, was approved for use in 2014 by regulatory agencies in the United States and Europe for the treatment of skin and skin structure infections. The activity of dalbavancin was also widely assessed by determination of its activity against Streptococcus pneumoniae clinical isolates collected from patients on six continents monitored during two time intervals (2011 to 2013 and 2014). A total of 18,186 pneumococcal isolates were obtained from 49 nations and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Community-acquired pneumonia.

The New England journal of medicine • 2015

MRSA: the first half century.

The Journal of antimicrobial chemotherapy • 2012

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2012